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Abstract 
A simple, precise, accurate, simultaneous stability indicating RP-HPLC method for the estimation of DLU 
(Duloxetin) and MCB (Methylcobalamine) in combined dosage form was developed using Intersil-C18 (4.6 x 250mm, 
5µm) in an Isocratic mode with mobile phase comprising of Phosphate buffer (pH 4.5) The flow rate was 1 mL/ min 
and effluent was monitored at 255.0 nm. The retention times were found to be 5.32 min for DLU and 3.59 min for 
MCB. The assay exhibited a linear dynamic range of 20- 120 µg/mL for DLU and 10- 60 µg/mL for MCB. The 
calibration curves were linear (r
2
 = 0.999 for DLU and r
2
 = 0.999 for MCB) over the entire linear range. Mean % 
recovery was found to be 99.68 % for DLU and 100.3 % for MCB with % RSD was NMT 2 for both estimations which 
fully agrees with system suitability which is in good agreement with labeled amount of formulation. The % RSD for 
Intra- Day & Inter-Day Precision was NMT than 2 for both the drugs. The developed method was validated as per ICH 
guidelines. 
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1. Introduction 
The technique High Performance Liquid 
Chromatography (HPLC) is so called because of its 
improved performance over the classical column 
chromatography. The technique basically involves the use 
of porous material as a stationary phase and the liquid 
mobile phase is pumped into the column under high 
pressure. The development of this technique is attributed 
to the small particle size of stationary phase. As the 
particle size is small the resistance to the flow of mobile 
phase is very high that is the reason why the high 
pressure is recommended.[1, 18] Analytical method 
development and validation are key elements of any 
pharmaceutical development program. HPLC analysis 
method is developed to identify, quantity or purifying 
compounds of interest. This technical brief will focus on 
development and validation activities as applied to drug 
products. Method validation is the process of proving that 
an analytical method is acceptable for its intended 
purpose. The parameters for method validation as defined 
by ICH (International Conference on Harmonization) 
guidelines are Accuracy, Precision, Specificity, Limit of 
Detection, Limit of Quantitation, Linearity, Range, 
Robustness and Ruggedness
2
. From the literature review 
[7-16] it has been found that only three analytical 
methods for the above combination have been reported. 
Therefore the attempt is made to develop simple, 
accurate, precise rapid and economical RP-HPLC method 
for determination of Duloxetin (DLU) and 
Methylcobalamine (MCB) in combine dosage form. 
Duloxetine hydrochloride (Figure 1) is a 
selective serotonin and norepinephrine reuptake inhibitor 
(SSNRI). IUPAC name of Duloxetine is ((3S)-N-Methyl-
3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine). 
This mainly used for the treatment of depression, anxiety 
and pain associated with diabetic peripheral neuropathy 
or fibromyalgia [1-4]. 
Methylcobalamin (Figure 2) IUPAC name is 
Coα-[α-(5,6-dimethylbenz-1H-imidazolyl)]-
Coβmethylcobamide. It is used in the treatment of 
trigeminal neuralgia, megaloplastic anemia, diabetic 
neuropathy and facial paralysis in Bell’s palsy syndrome. 
The combined dosage forms of these drugs are used for 
the treatment of neuropathic pain associated with 
peripheral neuropathy especially diabetic polyneuropathy 
[1-4]. 
Figure 1: Chemical Structure of Duloxetin 
 
Figure 2: Chemical Structure of Methyl cobalamine 
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2. Experimental 
2.1 Reagents & Chemicals 
Analytically pure sample of Duloxetine and 
Methylcobalamin with purities greater than 95% were 
obtained as gift samples from Chandra Labs, Hyderabad, 
India and tablet formulation [DUZELA M] was procured 
from Medplus pharmacy, Rajahmundry, India. with 
labelled amount 30mg and 1.5mg of Duloxetine and 
Methylcobalamin respectively. Acetonitrile (HPLC 
grade) was obtained from Sigma aldrich (Hyderabad, 
India), water (HPLC grade), Triethylamine (AR grade), 
ortho phosphoric acid (AR Grade) were obtained from 
SD Fine chemicals (Hyderabad, India), 0.22 and 0.45µm 
Nylon membrane filters were obtained from Spincotech 
Private Limited, Hyderabad, India. 
2.2 Instruments 
HPLC analysis was performed on Shimadzu LC-
20AD Prominence Liquid Chromatograph comprising a 
LC-20AD pump, Shimadzu SPD-20A Prominence UV-
VISIBLE detector and a reverse phase C18 column, 
Phenomenex Luna (250 X 4.6 mm; 5µ). A manually 
operating Rheodyne injector with 20 µL sample loop was 
equipped with the HPLC system. The HPLC system was 
controlled with “Lab so lutions lite” software. A double 
beam UV-visible spectrophotometer (Shimadzu, model 
UV-1800) having two matched quartz cells with 1 cm 
light path and loaded with UV probe software (version 
2.41) was used for recording of spectra and measuring 
absorbance. An electronic analytical weighing balance 
(0.1mg sensitivity, Shimadzu AY 220), digital pH meter 
(DELUX model 101), a sonicator (sonica, model 2200 
MH). 
2.3 Preparation of Standard Solutions  
2.3.1 Preparation of phosphate buffer 4.5: 
Weighed  6.8  grams  of  KH2PO4  was  taken  
into  a 1000ml  beaker,  dissolved  and diluted to 
1000ml with HPLC water, adjusted the pH to 4.6 
with ortho phosphoric acid. 
2.3.2 Preparation of mobile phase: 
A mixture of pH 4.6 Phosphate buffer 300 
mL (30%), 700 mL of ACN (70%) are taken and 
degassed in ultrasonic water  bath for 5 minutes.  Then 
this solution is filtered through 0.45 µ filter under 
vacuum filtration. 
2.3.3 Standard Stock Solution (A):  
200mg of Duloxetine HCl working standard 
was accurately weighed and transferred into a 100ml 
clean dry volumetric flask and about 2ml of DMF is 
added. Then it is sonicated to dissolve it completely and 
made volume upto the mark with the diluant.  Further 
10.0 ml from the above stock solution is pipette into 
a 100 ml volumetric flask and was diluted upto the 
mark with diluant.(10µg) 
 
2.3.4 Standard Stock Solution (B)  
Accurately weighed quantity of MCB (10.0 mg) 
was transferred to 100 mL volumetric flask and dissolved 
in mobile phase. The volume was made up to mark with 
mobile phase to get final concentration of 200 µg/mL. 
The resultant solution was then sonicated for 10.0 min in 
ultrasonicator. ).  Further 10.0 ml from the above stock 
solution is pipette into a 100 ml volumetric flask and 
was diluted upto the mark with diluant.(20µg) 
2.4 Optimization of Mobile Phase and 
Chromatographic Conditions 
2.4.1 Procedure:  
The chromatographic conditions were set as per 
the optimized parameters. The mobile phase was allowed 
to equilibrate with stationary phase as was indicated by a 
steady baseline. Solution (C) was injected in the 
Rheodyne injector (20.0 µl) and the respective 
chromatograms were recorded. Various mobile phases 
were tried by permutations and combinations and also by 
varying column, flow rate, column temperature and type 
of buffers with varying pH and solvents. The various 
mobile phases tried are as follows. 
 Trial 1 Water : Methanol (40: 60)  
 Trial 2 Buffer : Methanol (50: 50) 
 Trial 3  Buffer : Methanol (40: 60) 
 Trial 4 Buffer : Acetonitrile (40:60) 
 Trail 5 Buffer : Acetonitrile (30:70) 
Above mentioned mobile phases were tried. The 
mobile phase containing Phosphate buffer: Acetonitrile 
(30: 70) at pH 4.5, injection volume- 20.0 µL flow rate of 
1 mL/min was selected, due to its high resolving power, 
sensitivity and suitability, for the determination of DLU 
and MCB. The chromatogram is shown in Figure. Hence 
the following optimized chromatographic parameters 
were selected to carry out further experimentation. 
Column : Inertsil C18 (4.6 x 250mm, 5µm) 
Mobile phase : 
Phosphate buffer: Acetonitrile 
(30:70) 
pH : 4.5 (Using PDA) 
Flow Rate : 1 mL/min 
Wave length : 255.0 nm 
Injection volume : 20.0 µL 
Column 
temperature 
: Ambient 
Run time : 10.0 min 
2.5 System Suitability Studies 
System suitability is a pharmacopoeial 
requirement and is used to verify, whether the resolution 
and reproducibility of the chromatographic system are 
adequate for analysis to be carried out. It is performed to 
ensure that the system is operating properly and read to 
deliver results with acceptable accuracy and precision. 
The tests were performed by collecting data from five 
replicate injections of standard solutions. 
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Procedure:  
The chromatographic conditions were set as per 
the optimized parameters and mobile phase was allowed 
to equilibrate with stationary phase as was indicated by 
the steady baseline. Five replicate injections of mixed 
working standard solution (C) were injected in to the 
system, the chromatograms were recorded for both the 
drugs and the results are shown in Table 1 & 2. 
 
Fig. 3: Typical chromatogram of mixture of standard solutions 
2.6 Analysis of Marketed formulation 
2.6.1 Preparation of Sample Solutions 
Twenty tablets were weighed accurately and 
crushed to fine powder. Each tablet contains 30 mg of 
Duloxetine and 1.5 mg of MCB. A quantity of powder 
equivalent to 200 mg of DLU and 10mg of MCB was 
weighed and dissolved in 25 mL of the mobile phase in a 
100 mL volumetric flask. The volume was made up to 
give a concentration of 2000 μg/mL of DLU and 100 
μg/mL of MCB. The solution was filtered through 0.45 μ 
nylon membrane filter. From this filtrate, different 
dilutions ranging from 20-120 μg/mL of DLU & 10-
60μg/mL of MCB were prepared in 10 mL volumetric 
flasks with the mobile phase. 20 μL of each of these 
solutions were injected 5 times and the chromatograms 
were recorded. The amount of Duloxetine and 
Methylcobalamine present in each tablet formulation was 
calculated by comparing the peak area of the tablet 
solution with that of standard using the given formula: 
Equal volume (20.0 μL) of standard and sample 
solution was injected separately after equilibrium of 
stationary phase. The chromatograms were recorded and 
the response i.e. peak area of major peaks were measured. 
The amount of drug in a Tablet was calculated using 
following formula  
 
 
 
Table 1: System suitability test results 
Sr. No Parameters DUL MCB 
1 Peak area (mV*min) 2273955 754695 
2 No. of theoretical plates 5081 4011 
3 Retention time (min) 5.183 3.562 
4 Asymmetry 1.14 1.15 
 
3. Results and Discussion 
The chromatographic conditions were optimised 
to develop RP-HPLC method for simultaneous 
determination of Duloxetin and Methylcobalamine with 
adequate resolution and rapid analysis time. 
3.1 Method Validation: 
The analytical method was developed and 
validated according to ICH guidelines. Analytical 
variable parameters such as linearity, precision, accuracy, 
specificity and system suitability were tested using the 
optimized chromatographic conditions and instruments. 
 
3.1.1 Linearity: 
Mixed standard stock solution was suitably 
diluted with the mobile phase to obtain the concentrations 
ranging from 20-120 μg/mL of DUL & 10-60 μg/mL of 
MCB.. The solutions were filtered through 0.45 μ nylon 
membrane filter paper and 20 μL of each of the solutions 
were injected and the chromatograms were recorded. A 
good linear relationship (R
2
= 0.999 for Duloxetine and 
R
2
= 0.998 for Methylcobalamine was observed between 
the concentrations of the drugs and their corresponding 
peak areas. The results of linearity studies are shown in 
Table 2. 
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Table 2: Linearity study data for DLU and MCB 
S.No. Concentration of DUL Peak Area of DUL Concentration of MCB Peak Areak of MCB 
1 20 ppm 561876 10 ppm 187098 
2 40 ppm 1116970 20 ppm 370710 
3 60 ppm 1685203 30 ppm 560397 
4 80 ppm 2237066 40 ppm 744043 
5 100 ppm 2800383 50 ppm 934181 
6 120 ppm 3371108 60 ppm 1123745 
Correlation Coefficient 0.999 
 
Fig 4: Calibration curve of DUL 
 
 
Fig 5: Calibration curve of MCB 
 
 
3.1.2 Accuracy: 
The accuracy studies were performed on 50%, 
100 % and 150 % of the analytical method target 
concentrations of DUL and MCB. Standard and sample 
preparations were injected into HPLC system and three 
determinants for each concentration level were obtained. 
 
The percentage recoveries of Duloxetine and 
Methylcobalamine were calculated using standard at the 
same concentration at each concentration level. The 
results are presented in Table 3& 4. 
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Table 3: Results of Accuracy studies for Duloxetine 
 
Level (%) % Recovery % Mean Recovery %RSD 
50 100.072   
50 102.04 101.56 0.99 
50 101.35   
100 99.24   
100 99.55 100.12 1.27 
100 101.59   
150 104.87   
150 103.01 103.81 0.92 
150 103.56   
 
Table 4: Results of Accuracy studies for Methylcobalamin 
 
Level (%) % Recovery % Mean Recovery % RSD 
50 106.99   
50 103.94 105.65 1.47 
50 106.03   
100 95.41   
100 96.44 96.46 1.10 
100 97.54   
150 107.58   
150 107.58 106.98 0.98 
150 105.76   
 
3.1.3 Precision: 
System Precision:  
System precision of the proposed method was 
checked by injecting five replicate preparations of the 
standard drug solutions of Duloxetine (60μg/ml) and 
Methylcobalamine (30μg/ml). The corresponding peak 
areas were measured and % RSD calculated as exhibited 
in Table 5. 
 
 
Table 5: System precision results of Duloxetine and Methylcobalamin 
 
SI. No. RT Area RT Area 
1 5.351 2249906 3.576 750376 
2 5.332 2249724 3.561 750874 
3 5.326 2249452 3.597 751087 
4 5.370 2249197 3.532 751477 
5 5.337 2247457 3.542 751720 
6 5.319 2247088 3.539 751365 
Mean  2248804  751149.8 
Std.dev  1216.077  481.0977 
%RSD  0.054077  0.064048 
 
3.1.4 Specificity: 
The specificity of the proposed method was 
determined to check whether there is any interference 
due to presence of excipients, impurities or other 
components with the retention time of analytical peaks. 
The HPLC chromatograms were recorded for the drug-
matrix (mixture of the drug and excipient) which showed 
almost no interfering peaks within retention time ranges 
indicating that the method is quite specific. 
 
 
 
 
3.1.5 Robustness: 
Robustness of the developed analytical method 
was tested by evaluating the affect of small variations in 
analytical method parameters such as change in flow rate 
of 1.2 mL/min by ±0.2 mL/min and change in 
wavelength by ±2 nm. The results are shown in Table 6. 
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Table 6: Results of Robustness data 
Parameter 
Duloxetin Methylcobalamine 
Theoretical 
plates 
Tailing 
Factor 
Theoretical 
plates 
Tailing 
Factor 
Flow rate (0.8ml/min) 6118 1.14 4422 1.16 
Flow rate(1ml/min) 5533 1.12 4019 1.13 
Flow rate (1.2ml/min) 3593 1.16 3593 1.16 
Organic composition (10% less) 5688 1.16 4004 1.15 
Organic composition (Actual) 5533 1.12 4019 1.13 
Organic composition (10% more) 5351 1.16 3814 1.18 
 
4. Application of the method to commercial 
formulations 
Twenty tablets were weighed accurately and 
crushed to fine powder. Each tablet contains 30 mg of 
Duloxetine and 1.5 mg of MCB. A quantity of powder 
equivalent to 200 mg of DLU and 10mg of MCB was 
weighed and dissolved in 25 mL of the mobile phase in a 
100 mL volumetric flask. The volume was made up to 
give a concentration of 2000 μg/mL of DLU and 100 
μg/mL of MCB. The solution was filtered through 0.45 μ 
nylon membrane filter. From this filtrate, different 
dilutions ranging from 20-120 μg/mL of DLU & 10-
60μg/mL of MCB were prepared in 10 mL volumetric 
flasks with the mobile phase. 20 μL of each of these 
solutions were injected 5 times and the chromatograms 
were recorded. The amount of Duloxetine and 
Methylcobalamine present in each tablet formulation was 
calculated by comparing the peak area of the tablet 
solution with that of standard using the given formula. 
 
 
 
Table7: Results of Marketed Formulation Analysis 
S. No. 
Weight of std Weight of Sample (mg) Peak area of Peak area of % Label 
DUL MCB  DUL MCB DUL MCB DUL MCB 
1 
200 10 
312.20 2255315 752297 2255474 752347 99.98 99.99 
2 312.12   2255489 752115 99.99 100.02 
3 312.35   2255290 752367 100.00 99.99 
Mean 99.99 100.00 
S.D. 0.01 0.02 
%RSD 0.01 0.02 
 
Fig 6: Typical HPLC Chromatogram corresponding to marketed formulation of DUL and MCB 
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5. Conclusion 
The proposed RP-HPLC method is simple, 
sensitive, reproducible, less time consuming and is 
applicable for analysis of Duloxetine and 
Methylcobalamine in bulk and in tablet dosage forms. 
The method was duly validated by evaluation of required 
parameters 
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